Previous 10 | Next 10 |
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced its February 4, 2020 receipt of notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the ...
Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX ), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, announced that it received notice from The Nasdaq Sto...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today provided a clinical update and focus for its Oncoprex(TM) immunogene therapy program for 2020. According to the u...
Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX ), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today provides a clinical update and focus for its On...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that it will present at the Noble Capital Markets 16th Annual Investor Conference. Genprex’s pre...
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, announced that the Company will present at the Noble ...
Lee Enterprises (NYSE: LEE ) +55% to acquire BH Media Group’s publications and The Buffalo News for $140M. More news on: Lee Enterprises, Incorporated, Hepion Pharmaceuticals, Inc., Genprex, Inc., Stocks on the move, , Read more ...
Study results show TUSC2 overexpression decreased thyroid cancer tumor metastasis and increased sensitivity to apoptosis by increasing SMAC/DIABLO and Cytochrome C protein levels Study highlights the possibility that TUSC2 may also be effective in thyroid cancer therapy and adds to...
Ocean Bio-Chem (NASDAQ: OBCI ) +80% as its subsidiary Star brite announces registered EPA product kills the Coronavirus . More news on: Ocean Bio-Chem, Inc., Happiness Biotech Group Limited, Delphi Technologies PLC, Stocks on the move, , Read more ...
Capital raise follows recent Fast Track Designation by the FDA for Company’s Oncoprex™ imunogene therapy for NSCLC in combination therapy with AstraZeneca’s Tagrisso® Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a ...
News, Short Squeeze, Breakout and More Instantly...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer PR Newswire Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024 Acclaim-3 Study Suppor...